Date: 2015-06-10
Type of information: Financing round
Company: Melinta Therapeutics (USA - CT)
Investors: Malin Corporation (Ireland) Vatera Healthcare Partners (USA - NY) other undisclosed existing investors
Amount: $67 million
Funding type: financing round
Planned used: Melinta Therapeutics will use these funds to complete the final Phase 3 study of delafloxacin, an investigational fluoroquinolone, undergoing a confirmatory Phase 3 study for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). Funds will also support the potential submission of a New Drug Application (NDA) for delafloxacin for the lead indication, pursuing new indications for delafloxacin including hospital-treated community-acquired bacterial pneumonia (hCABP), and advancing a lead candidate for the company’s ESKAPE pathogen program.
Others: • On June 10, 2015, Melinta Therapeutics announced the successful completion of a $67 million Series 4 equity financing. Malin Corporation led the round and was joined by other existing investors, including Vatera Healthcare Partners.
Therapeutic area: Infectious diseases
